Javascript must be enabled to continue!
ReCAP: Cost Differential of Chemotherapy for Solid Tumors
View through CrossRef
QUESTION ASKED: The objective of the present study is to determine the cost differentials between chemotherapeutic regimens (of similar or acceptable effectiveness) for common solid tumors in the metastatic and adjuvant settings. SUMMARY ANSWER: Of the 62 regimens included, the 6-month mean cost of chemotherapy was $26,989, and the median cost was $9,611. Mean cost of metastatic cancer therapy regimens was $35,315 compared with $18,107 for curative therapy. Regimens using biologics had higher mean costs than regimens not using biologics ($77,278 v $13,646). Cost differential between extremes of costs for regimens with presumed similar efficacy was Δ$90,843; $79,165 in the curative therapy arms and $90,210 in the metastatic cancer therapy arms. The highest cost differential was noted in breast cancer regimens (Δ$71,041 for metastatic v Δ$63,926 for curative). METHODS: Chemotherapy regimens—curative (adjuvant/neoadjuvant) and metastatic—and dosages outlined in National Comprehensive Cancer Network guidelines (2013) were acquired for four common cancers: bladder, breast, colon, and lung. Baseline drug and treatment costs were calculated for the average US adult male using the payment allowance for Medicare part B drugs database (2013). Costs were extrapolated for a treatment period of 6 months. BIAS, CONFOUNDING FACTOR(S), DRAWBACKS: The calculations used payer perspective for the drug and the reimbursement, which may not truly reflect the actual costs incurred by the individual or society. However, the simplicity provides the strength of inferences which are fairly robust across the sensitivity analysis. REAL-LIFE IMPLICATIONS: A significant cost differential exists between chemotherapeutic regimens for the commonest solid tumors. In the absence of existing cost-effectiveness guidelines, cost differentials can help practicing oncologists in financially sound decision making regarding choosing therapy. Incorporation of costs and incremental effectiveness in currently established guidelines may encourage socially responsible practice patterns.
American Society of Clinical Oncology (ASCO)
Title: ReCAP: Cost Differential of Chemotherapy for Solid Tumors
Description:
QUESTION ASKED: The objective of the present study is to determine the cost differentials between chemotherapeutic regimens (of similar or acceptable effectiveness) for common solid tumors in the metastatic and adjuvant settings.
SUMMARY ANSWER: Of the 62 regimens included, the 6-month mean cost of chemotherapy was $26,989, and the median cost was $9,611.
Mean cost of metastatic cancer therapy regimens was $35,315 compared with $18,107 for curative therapy.
Regimens using biologics had higher mean costs than regimens not using biologics ($77,278 v $13,646).
Cost differential between extremes of costs for regimens with presumed similar efficacy was Δ$90,843; $79,165 in the curative therapy arms and $90,210 in the metastatic cancer therapy arms.
The highest cost differential was noted in breast cancer regimens (Δ$71,041 for metastatic v Δ$63,926 for curative).
METHODS: Chemotherapy regimens—curative (adjuvant/neoadjuvant) and metastatic—and dosages outlined in National Comprehensive Cancer Network guidelines (2013) were acquired for four common cancers: bladder, breast, colon, and lung.
Baseline drug and treatment costs were calculated for the average US adult male using the payment allowance for Medicare part B drugs database (2013).
Costs were extrapolated for a treatment period of 6 months.
BIAS, CONFOUNDING FACTOR(S), DRAWBACKS: The calculations used payer perspective for the drug and the reimbursement, which may not truly reflect the actual costs incurred by the individual or society.
However, the simplicity provides the strength of inferences which are fairly robust across the sensitivity analysis.
REAL-LIFE IMPLICATIONS: A significant cost differential exists between chemotherapeutic regimens for the commonest solid tumors.
In the absence of existing cost-effectiveness guidelines, cost differentials can help practicing oncologists in financially sound decision making regarding choosing therapy.
Incorporation of costs and incremental effectiveness in currently established guidelines may encourage socially responsible practice patterns.
Related Results
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Renal Ewing Sarcoma: A Case Report and Literature Review
Renal Ewing Sarcoma: A Case Report and Literature Review
Abstract
Introduction
Primary renal Ewing sarcoma is an extremely rare and aggressive tumor, representing less than 1% of all renal tumors. This case report contributes valuable in...
Abstract 720: Comparison of the gut microbiome between children with solid tumor receiving chemotherapy and healthy children
Abstract 720: Comparison of the gut microbiome between children with solid tumor receiving chemotherapy and healthy children
Abstract
Background: Chemotherapy is commonly used for children with cancer. Intensive chemotherapy can disturb the gut microbiome, which may be associated with trea...
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Differential Diagnosis of Neurogenic Thoracic Outlet Syndrome: A Review
Abstract
Thoracic outlet syndrome (TOS) is a complex and often overlooked condition caused by the compression of neurovascular structures as they pass through the thoracic outlet. ...
Changes in oral microbiota after the initiation of chemotherapy in patients with hematopoietic tumors
Changes in oral microbiota after the initiation of chemotherapy in patients with hematopoietic tumors
Abstract
Background
Recently, the gut microbiota has been shown to play an important role in the response and resistance to chemotherapy. Although there is much knowledge ...
Central nervous system
Central nervous system
Several different types of tumors, benign and malignant, have been identified in the central nervous system (CNS). The prognoses for these tumors are related to several factors, su...

